How A Biologics CDMO Adds Value To mAbs Development & Manufacturing Programs

The therapeutic landscape has witnessed a surge in monoclonal antibodies (mAbs), accompanied by advancements in their process development and manufacturing. This has fostered the crucial role of contract development and manufacturing organizations (CDMOs) in propelling mAb programs toward expedited commercialization. This infographic delves into the multifaceted value proposition offered by an experienced biologics CDMO throughout a mAb's lifecycle.